|
Tumor Cell Invasion
|
0.070 |
Biomarker
|
phenotype |
BEFREE |
LncRNA DLEU1/microRNA-300/RAB22A axis regulates migration and invasion of breast cancer cells.
|
31841195 |
2019 |
|
Tumor Cell Invasion
|
0.070 |
Biomarker
|
phenotype |
BEFREE |
LncRNA SNHG3/miRNA-151a-3p/RAB22A axis regulates invasion and migration of osteosarcoma.
|
30797154 |
2019 |
|
Tumor Cell Invasion
|
0.070 |
PosttranslationalModification
|
phenotype |
BEFREE |
In this study, we found that silencing of Rab22a suppressed the migration and invasion of lung cancer cells.
|
28433697 |
2017 |
|
Tumor Cell Invasion
|
0.070 |
Biomarker
|
phenotype |
BEFREE |
Targeting newly identified RAB22A with miR-204 may aid in the suppression of RCC proliferation and invasion.
|
26883716 |
2016 |
|
Tumor Cell Invasion
|
0.070 |
Biomarker
|
phenotype |
BEFREE |
Rab22a knockdown inhibited invasion and migration of EOC cells, increased E-cadherin expression, and suppressed the expression of N-cadherin.
|
25460499 |
2014 |
|
Tumor Cell Invasion
|
0.070 |
Biomarker
|
phenotype |
BEFREE |
Hypoxia-inducible factors and RAB22A mediate formation of microvesicles that stimulate breast cancer invasion and metastasis.
|
24938788 |
2014 |
|
Tumor Cell Invasion
|
0.070 |
Biomarker
|
phenotype |
BEFREE |
Primary melanoma in patients greater than 60 years old was characterized by the increased expression of miRs regulating TLR-MyD88-NF-kappaB pathway (hsa-miR-199a), RAS/RAB22A pathway (hsa-miR-204); growth differentiation and migration (hsa-miR337), epithelial mesenchymal transition (EMT) (let-7b, hsa-miR-10b/10b*), invasion and metastasis (hsa-miR-10b/10b*), hsa-miR-30a/e*, hsa-miR-29c*; cellular matrix components (hsa-miR-29c*); invasion-cytokinesis (hsa-miR-99b*) compared to melanoma of younger patients.
|
20302635 |
2010 |
|
Neoplasm Metastasis
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
On the whole, the findings of this study demonstrate the critical role that miR-193b plays in the regulation of RAB22A-mediated exosome function during cancer growth and metastasis, which may have significant implications on cancer therapy.
|
30272274 |
2018 |
|
Neoplasm Metastasis
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
Furthermore, Rab22A reversal downregulated the inhibitory effect of miR-520b. miR-520b expression was downregulated in NSCLC, which was negatively correlated with lymph node metastasis and TNM staging. miR-520b targeted on Rab22A to work as a tumor suppressor, inhibiting tumor proliferation and metastasis.
|
30402147 |
2018 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Furthermore, Rab22A reversal downregulated the inhibitory effect of miR-520b. miR-520b expression was downregulated in NSCLC, which was negatively correlated with lymph node metastasis and TNM staging. miR-520b targeted on Rab22A to work as a tumor suppressor, inhibiting tumor proliferation and metastasis.
|
30402147 |
2018 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
In addition, RAB22A was found to be a target of miR-203, a tumor suppressive miRNA in melanoma.
|
27690221 |
2016 |
|
Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
Take together, our results demonstrated that miR-203 act as a tumor suppressor miRNA through regulating RAB22A expression and suggested its involvement in osteosarcoma progression and carcinogenesis.
|
26382657 |
2015 |
|
Neoplasm Metastasis
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
In breast cancer patients, RAB22A mRNA overexpression in the primary tumor is associated with decreased overall and metastasis-free survival and, in an orthotopic mouse model, RAB22A knockdown impairs breast cancer metastasis.
|
24938788 |
2014 |
|
Neoplasm Metastasis
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
MiR-373 targeting of the Rab22a oncogene suppresses tumor invasion and metastasis in ovarian cancer.
|
25460499 |
2014 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Our results demonstrate for the first time that miR-204-5p acts as a tumor suppressor in colorectal cancer through inhibiting RAB22A and reveal RAB22A to be a new oncogene and prognostic factor for colorectal cancer.
|
25294901 |
2014 |
|
Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
In breast cancer patients, RAB22A mRNA overexpression in the primary tumor is associated with decreased overall and metastasis-free survival and, in an orthotopic mouse model, RAB22A knockdown impairs breast cancer metastasis.
|
24938788 |
2014 |
|
Neoplasm Metastasis
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
Primary melanoma in patients greater than 60 years old was characterized by the increased expression of miRs regulating TLR-MyD88-NF-kappaB pathway (hsa-miR-199a), RAS/RAB22A pathway (hsa-miR-204); growth differentiation and migration (hsa-miR337), epithelial mesenchymal transition (EMT) (let-7b, hsa-miR-10b/10b*), invasion and metastasis (hsa-miR-10b/10b*), hsa-miR-30a/e*, hsa-miR-29c*; cellular matrix components (hsa-miR-29c*); invasion-cytokinesis (hsa-miR-99b*) compared to melanoma of younger patients.
|
20302635 |
2010 |
|
Malignant Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
In addition, the present findings suggested that the increased expression of miR-193b by RAB22A, inhibited downstream proteins involved in the Ras signaling pathway, including the Ras and extracellular signal-related kinase which may inhibit cancer proliferation and migration.
|
31007734 |
2019 |
|
Osteosarcoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
LncRNA SNHG3/miRNA-151a-3p/RAB22A axis regulates invasion and migration of osteosarcoma.
|
30797154 |
2019 |
|
Osteosarcoma of bone
|
0.030 |
Biomarker
|
disease |
BEFREE |
LncRNA SNHG3/miRNA-151a-3p/RAB22A axis regulates invasion and migration of osteosarcoma.
|
30797154 |
2019 |
|
Childhood Osteosarcoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
LncRNA SNHG3/miRNA-151a-3p/RAB22A axis regulates invasion and migration of osteosarcoma.
|
30797154 |
2019 |
|
Malignant neoplasm of breast
|
0.030 |
Biomarker
|
disease |
BEFREE |
While RAB22A was found to regulate exosomes-mediated breast cancer cell proliferation, invasion and migration, these biological characteristics were diminished in the breast cancer cells in which the RAB22A gene was knocked down or in the cells in which the exosomes were dissolved by proteinase K/RNase treatment.
|
30272274 |
2018 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
On the whole, the findings of this study demonstrate the critical role that miR-193b plays in the regulation of RAB22A-mediated exosome function during cancer growth and metastasis, which may have significant implications on cancer therapy.
|
30272274 |
2018 |
|
Breast Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
While RAB22A was found to regulate exosomes-mediated breast cancer cell proliferation, invasion and migration, these biological characteristics were diminished in the breast cancer cells in which the RAB22A gene was knocked down or in the cells in which the exosomes were dissolved by proteinase K/RNase treatment.
|
30272274 |
2018 |
|
Osteosarcoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Rab22a is overexpressed in different cancer types, including liver cancer, malignant melanoma, ovarian cancer and osteosarcoma.
|
28433697 |
2017 |